The discovery of MFSD2A and LPC-mediated transport of EPA and DHA is a major scientific breakthrough with widespread implications and exciting potential clinical application areas. LYSOVETA™ by Aker BioMarine is the first LPC-EPA/DHA composition offered at scale, and for free, to the research community. We invite you to explore the original published research and to contact us for future collaboration opportunities.